Cyclopharm (ASX:CYC) Technegas Phase 3 Trial meets primary endpoint

Latest Company News - Finance News Network

English - September 28, 2020 03:00 - 5 minutes - 1000 KB
Business News News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Market update with Shaw and Partners, September 2020

Next Episode: Respiri (ASX:RSH) asthma care beyond the clinic

28 Sep 2020 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO James McBrayer provides an update on the company's US Phase 3 trial for Technegas, and USFDA approval process timeline, with commercial sales expected in the US for 2021.